Diabetic nephropathy Market Expected to Reach $3.3 Billion by 2031

According to a new report published by Allied Market Research, titled, “Diabetic nephropathy Market," The diabetic nephropathy market was valued at $1.9 billion in 2021, and is estimated to reach $3.3 billion by 2031, growing at a CAGR of 6% from 2022 to 2031.

Diabetic nephropathy is the metabolic disorder in which the body has high sugar levels for prolonged period. Diabetes is of two types i.e., type-1 and type-2. Diabetic nephropathy is a medical condition in which diabetes affect kidney and causes chronic kidney diseases and kidney disorders. Diabetic nephropathy is one of the most significant complications, in terms of mortality and morbidity for patients with diabetes. It affects the ability of kidneys to do their usual work of removing waste products and extra fluid from body. The best way to prevent or delay diabetic nephropathy is by maintaining a healthy lifestyle and adequately managing your diabetes and high blood pressure. Kidney disease may progress to kidney failure, also called end-stage kidney disease. Kidney failure is a life-threatening condition. At this stage, treatment options are dialysis or a kidney transplant.

Hypertension or high blood pressure and high cholesterol is a complication of diabetes that is believed to contribute directly to diabetic nephropathy. Therefore, anti-hypertensive drug and anti-hyperlipidemic drug is used to treat diabetic kidney diseases.    

Diabetic nephropathy market growth is majorly driven by rise in geriatric population, surge in number of patients suffering from diabetes, chronic renal disease, atherosclerosis, and hypertension. Globally, the diabetic nephropathy market size is witnessing significant growth, owing to increase in prevalence of diabetes and obesity in different regions of the world. In addition, rise in R&D investments in drug discovery and development and rise in awareness regarding diabetes and kidney-related disorders.

For instance, according to latest reports of the Indian Council of Medical Research, there were around 150% increment in diabetes cases in India in 2021. For instance, according to the International Diabetes Federation (IDF) Atlas Tenth edition 2021, approximately 537 million adults (20–79 years) are living with diabetes. More than 1.2 million children and adolescents (0–19 years) are living with type 1 diabetes, 541 million adults are at increased risk of developing type 2 diabetes, and 1 in 6 live births (21 million) are affected by diabetes during pregnancy.

For instance, according to the 9th edition of International Diabetes Federation, 463 million people are currently affected by diabetes globally, and it is expected to increase to 642 million by 2040.

Thus, above-mentioned factors are anticipated to fuel adoption of medicinal products against diabetic nephropathy disease. Furthermore, the market is highly competitive in nature, with major players focusing on creating awareness regarding diabetic nephropathy. Major players in the diabetic nephropathy market host exhibition and seminars to display and promote use of diabetic nephropathy for diverse medical applications.

In addition, diabetic nephropathy market trends such as discovery and development; launch of various products; and strategies among key players such as acquisition, collaboration, and agreement drive the diabetic nephropathy market. For instance, in 2021, ASTRAZENECA got the approval in Japan and Europe for Forxiga as its key developmental strategy to sustain the intense competition and improve its product portfolio.

However, the sales of diabetic nephropathy medicine have witnessed hindrances, owing to the strict government regulations on the quality of ingredient and excipients that are used in it. Strict regulatory rules regarding selling and lengthy drug approval times also hamper the market growth. On the contrary, surge in healthcare investments in public as well as private sectors, increase in patient population, and unmet medical demands in developing economies in mostly countries are anticipated to open new avenues for expansion of the diabetic nephropathy market during the forecast period.

By drug class type, the angiotensin-converting enzyme inhibitors segment was the highest revenue contributor to the market in 2021, owing to rise in number of temporary as well as permanent chronic heart disease, heart attack, hypertension, and diabetic nephropathy. The diuretics segment is expected to witness highest CAGR during the forecast period, owing to rise in awareness and surge in cases of oedema, hypertension, kidney stones, and diabetic nephropathy.

On the basis of types, the type-2 diabetes segment generated maximum revenue in 2021, owing to surge in diabetes cases and increase in awareness and diagnosis of diabetic nephropathy. The type-2 diabetes segment is also expected to witness highest CAGR during the forecast period.

On the basis of distribution channel, the drug stores & retail pharmacy segment was the highest revenue contributor to the diabetic nephropathy market share in 2021. The online providers segment is expected to witness highest CAGR during the forecast period, owing to increase in population suffering from diabetes and geriatric population.

In diabetic nephropathy industry, North America generated maximum revenue in 2021, owing to increase in number of patient admissions and chronic kidney diseases. Asia-Pacific is expected to witness highest CAGR during the forecast period, owing to surge in number of diabetic nephropathy cases, chronic heart disease cases, and increase in prevalence of hypertension.

KEY FINDINGS OF THE STUDY 
•    Based on product type, the stent segment held the largest share in the U.S. market in 2021 and is expected to remain dominant during the forecast period.
•    Based on procedure type, the balloon angioplasty segment held the largest share in the U.S. market in 2021.
•    On the basis of application, the cardiology held the largest share in the U.S. market in 2021. 
•    On the basis of end user, the hospitals segment held the largest share in U.S. market in 2021.